CARDINAL HEALTH INC (CAH)

US14149Y1082 - Common Stock

111.76  -0.28 (-0.25%)

Buy % Consensus

72

ChartMill assigns a Buy % Consensus number of 72% to CAH. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 117.59. This target is 5.22% above the current price.
CAH was analyzed by 22 analysts. The buy percentage consensus is at 72. So analysts seem to be have mildly positive about CAH.
In the previous month the buy percentage consensus was at a similar level.
CAH was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 111.7696.96117.81117.59139.65 - -13.24% 5.41% 5.22% 24.96%
Up and Down Grades
Date Firm Action Rating
2024-02-26 Leerink Partners Initiate Outperform
2024-02-09 Argus Research Upgrade Hold -> Buy
2024-02-05 UBS Maintains Buy -> Buy
2024-01-29 UBS Maintains Buy -> Buy
2024-01-03 Barclays Initiate Overweight
2023-12-14 Wells Fargo Initiate Underweight
2023-11-17 JP Morgan Maintains Neutral -> Neutral
2023-08-16 TD Cowen Maintains Market Perform -> Market Perform
2023-08-16 Mizuho Maintains Neutral -> Neutral
2023-08-16 JP Morgan Maintains Neutral -> Neutral
2023-08-16 Baird Maintains Outperform -> Outperform
2023-08-16 Morgan Stanley Maintains Overweight -> Overweight
2023-07-11 Mizuho Maintains Neutral -> Neutral
2023-07-10 Evercore ISI Group Downgrade Outperform -> In-Line
2023-06-12 UBS Maintains Buy
2023-06-12 Barclays Maintains Equal-Weight
2023-06-12 Credit Suisse Maintains Neutral -> Neutral
2023-06-12 Citigroup Maintains Neutral -> Neutral
2023-06-09 JP Morgan Maintains Neutral -> Neutral
2023-05-08 Deutsche Bank Maintains Hold
2023-05-08 Citigroup Maintains Neutral
2023-05-05 Barclays Maintains Equal-Weight
2023-04-26 Deutsche Bank Maintains Hold
2023-03-31 Citigroup Initiate Neutral
2023-03-22 Deutsche Bank Maintains Hold
2023-02-03 Baird Upgrade Neutral -> Outperform
2023-02-03 Credit Suisse Maintains Neutral
2023-02-03 Morgan Stanley Maintains Overweight
2023-01-31 UBS Maintains Buy
2023-01-06 Morgan Stanley Maintains Overweight